Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Direct Oral Anticoagulants (DOACs) Device Market Between 2025 And 2029?
The direct oral anticoagulants (DOACs) device market size has witnessed significant expansion in recent years. It is projected to increase from $30.10 billion in 2024 to $32.80 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to several factors, including the increasing prevalence of cardiovascular disorders, the rising incidence of atrial fibrillation, greater awareness regarding stroke prevention, a surge in anticoagulant prescriptions, and the growing geriatric population.
The market for direct oral anticoagulants (DOACs) devices is projected to experience substantial expansion over the upcoming years. By 2029, this market is anticipated to reach a valuation of $45.65 billion, expanding at a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include the increasing uptake of personalized medicine, a rising inclination towards managing anticoagulants at home, a heightened need for swift diagnostic instruments, greater awareness about preventing strokes, and the expanding healthcare infrastructure within developing economies. Key trends expected in the forecast timeframe encompass the incorporation of smart sensors into monitoring devices, the creation of point-of-care testing solutions for direct oral anticoagulants, ongoing advancements in drug delivery systems, their integration into standard clinical procedures, and technological improvements in tools designed to enhance patient adherence.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp
Which Drivers Are Supporting Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?
The market for direct oral anticoagulants (DOACs) devices is projected to expand due to the rising occurrence of cardiovascular disorders. These disorders encompass various ailments affecting the heart and blood vessels, frequently resulting in complications like heart attacks, strokes, or other problems within the circulatory system. The increase in cardiovascular disorders is linked to increasingly sedentary lifestyles, which, over time, contribute to weight gain, higher blood pressure, and diminished cardiovascular function. Direct oral anticoagulants (DOACs) assist in managing cardiovascular conditions by effectively reducing the likelihood of stroke and blood clots for individuals with atrial fibrillation, providing consistent anticoagulation without requiring regular blood tests. For example, as reported in January 2025 by the American Heart Association, a US-based nonprofit organization, cardiovascular disease led to 941,652 deaths in the US in 2022, representing an increase of over 10,000 deaths compared to the 931,578 recorded in 2021. Consequently, the growing incidence of cardiovascular disorders is a key factor propelling the expansion of the direct oral anticoagulants (DOACs) device market.
What Are The Different Segment Classifications Within The Direct Oral Anticoagulants (DOACs) Device Market?
The direct oral anticoagulants (DOACs) device market covered in this report is segmented
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate
Which Key Trends Are Expected To Influence The Direct Oral Anticoagulants (DOACs) Device Market In The Coming Years?
Leading companies within the direct oral anticoagulants (DOACs) device market are concentrating on developing sophisticated solutions, notably automated coagulation assays, to enhance the accuracy, efficiency, and consistency of direct oral anticoagulant level monitoring in clinical laboratories. These automated coagulation assays are machine-performed laboratory tests that gauge blood clotting speed, assisting in the diagnosis of bleeding or clotting disorders. For example, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, introduced three new coagulation tests specifically designed for Factor Xa inhibitors. These innovations empower clinicians to more precisely evaluate the anticoagulation status of patients on direct Factor Xa inhibitors such as rivaroxaban and apixaban. They further assist clinical decision-making by accurately measuring the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical situations like bleeding, overdose, or urgent surgery. Leveraging Roche’s reagent cassette technology on cobas t analyzers, these automated tests ensure high-quality outcomes, minimize manual processing, and optimize laboratory workflow efficiency.
Which Key Market Players Are Investing In Expansion And Innovation Of Direct Oral Anticoagulants (DOACs) Device Market?
Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Direct Oral Anticoagulants (DOACs) Device Industry?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Direct Oral Anticoagulants (DOACs) Device Market Report:
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp
Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2025, By The Business Research Company
Financial Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/financial-services-global-market-report
Machine Learning Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/machine-learning-global-market-report
Financial Analytics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model